Curcuma longa improves endothelial glycocalyx integrity and redox-inflammatory pathways in type 2 diabetes mellitus: a randomized double-blind placebo-controlled study.
- 2026-04
- European journal of nutrition 65(3)
- Drielly Rodrigues Viudes
- Alanna Ramalho Mateus
- Cristina Antoniali Silva
- Maria do Carmo Franco
- PubMed: 41984245
- DOI: 10.1007/s00394-026-03963-3
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Population
- 76 adults with type 2 diabetes mellitus (T2DM)
- Methods
- randomized, double-blind, placebo-controlled trial; CLE (1200 mg/day) or placebo for three months
- Blinding
- Double-blind
- Duration
- three months
- Funding
- Unclear
- Rigorous Journal
Research Insights
CLE increased antioxidant/redox markers Nrf2 (P < 0.05)
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 1200 mg/day
CLE increased antioxidant/redox markers SIRT1 (P < 0.05)
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 1200 mg/day
CLE increased antioxidant/redox markers Trx1 (P < 0.05)
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 1200 mg/day
CLE significantly reduced markers of endothelial glycocalyx shedding, including HA (259.8 vs. 371.7 ng/mL; P = 0.002)
- Effect
- Beneficial
- Effect size
- Moderate
- Dose
- 1200 mg/day
HA (259.8 vs. 371.7 ng/mL; P = 0.002)
- Effect
- Beneficial
- Effect size
- Moderate
- Dose
- 1200 mg/day
CLE significantly reduced MMP-2 (198.4 vs. 233.3 ng/mL; P < 0.001)
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 1200 mg/day
CLE significantly reduced MMP-9 (1.2 vs. 2.0 ng/mL; P < 0.001)
- Effect
- Beneficial
- Effect size
- Moderate
- Dose
- 1200 mg/day
reduced TBP2 and NF-κB p65 levels (both P < 0.001)
- Effect
- Beneficial
- Effect size
- Large
- Dose
- 1200 mg/day
CLE supplementation resulted in a significant reduction in neuropathy symptom score compared with placebo (P = 0.048)
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 1200 mg/day
CLE reduced NF-κB p65 levels (P < 0.001)
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 1200 mg/day
CLE significantly reduced markers of endothelial glycocalyx shedding, including SDC1 (66.5 vs. 113.0 ng/mL; P = 0.001)
- Effect
- Beneficial
- Effect size
- Moderate
- Dose
- 1200 mg/day
CLE significantly reduced markers of endothelial glycocalyx shedding, including SDC4 (155.1 vs. 225.5 pg/mL; P = 0.040)
- Effect
- Beneficial
- Effect size
- Moderate
- Dose
- 1200 mg/day
CLE reduced TBP2 (P < 0.001)
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 1200 mg/day
reduced TBP2 and NF-κB p65 levels (both P < 0.001)
- Effect
- Beneficial
- Effect size
- Large
- Dose
- 1200 mg/day